^
Association details:
| Biomarker: | ARID1A mutation |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Rubraca (rucaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium
Published date:
04/28/2022
Excerpt:
Thirty-three patients with recurrent cervical or endometrial cancer were enrolled. Patients were required to have tumor progression after first line treatment for metastatic, or recurrent disease. Rucaparib was given at 600 mg BID twice daily for each 21-day cycle. Bevacizumab was given at 15 mg/kg on day 1 of each 21-day cycle....Patients with ARID1A mutations displayed a better response rate (33%) and 6-month progression free survival (PFS6) rate (67%) than the entire study population.
DOI:
10.1016/j.ygyno.2022.04.016
